Depomed tries to bounce back

Share of Depomed (DEPO +10.6%) try to recoup some of yesterday's post-earnings-report loss. Prices are off ~10% from the intraday high of $12.83 but still cling to a decent gain on modestly higher volume.

Consensus estimates for Q2 and Q3 are EPS of $0.03 on revenues of $40M and $0.10/share on revenues of $48.4M, respectively.

Consensus views for 2014 and 2015 are EPS of $0.31 on revenues of $208.1M and EPS of $.20 on revenues of $184M, respectively.

175 mutual funds have positions, up from 134 a year earlier.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs